ARTIFICIAL INTELLIGENCE

INVEST IN

SWISS-CANADIAN
Ai MED-TECH

Targeting 5x ROI*

“MRI scans are growing at a rate far outpacing radiologists’ capacity.”

• Non-standardised radiology reports are open to misinterpretation.
  
• Radiologists cannot devote more than 3 seconds per MRI scan.
• MRI diagnosis requires specialised skills and experienced radiologists.
• Work is repetitive and quality-challenged work for Radiologists.

The Company has developed cutting-edge MRI Ai technology, which uses algorithms to consistently improve diagnostic skills’ quality, reducing subjectivity and ambiguity.

This Ai technology means fewer patients are misdiagnosed, resulting in better treatments for patients, lower compensation pay-outs and reduced insurance premiums.

THE NEED

THE SOLUTION - DISRUPTIVE Ai TECHNOLOGY

*EXIT STRATEGY TARGETING 5X VIA IPO OR A TRADE SALE TO A MAJOR MEDTECH PLAYER CIRCA TWO YEARS.

Founded 2015, having received substantial R&D funding, the Company has spent seven years developing leading Ai technology, already in use in Swiss Hospitals, proof of product and successful clinical trials conducted.

Pre-submission to the FDA, focused on Spine, Knee, and Shoulder. The Ai promises a comprehensive, multi-pathology Ai solution.

Market players are lagging; MedTech firms such as Canon Medical, Philips Healthcare, Boston Scientific and Siemens Ingenuity seek to integrate innovative proprietary Ai technology into their tech platforms.

EARLY INNOVATOR

Disclaimer: Any person accessing the email and considering potential investment opportunities featured on the email should make their own commercial assessment of an investment opportunity after seeking the advice of an appropriately authorised or regulated financial advisor. This email should not be construed as advice or a personal recommendation to any prospective investor by Indigo Alternatives. Investments of this nature carry risks to your capital and can go up or down. Past performance is not indicative of future results. Suitable appropriately qualified investors, sophisticated and high net worth investors only.